Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Business Context and Reporting Period
Phathom Pharmaceuticals, a clinical-stage biopharmaceutical company, filed a Current Report on Form 8-K dated May 20, 2020, with additional annual-meeting results reported for the May 21, 2020 stockholders’ meeting. The filing covers executive compensation changes and voting outcomes.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material Changes
- Effective July 1, 2020, CEO Terrie Curran’s annual base salary increased to $535,000, and her annual target bonus increased to 60% of base salary.
- Effective July 1, 2020, COO Azmi Nabulsi’s annual base salary increased to $482,500, and his annual target bonus increased to 50% of base salary.
- The company stated that its Bonus Plan would be amended to reflect these changes, with the amended plan to be filed as an exhibit to its Form 10-Q for the quarter ending June 30, 2020.
Annual Meeting and Outlook
- Stockholders elected Terrie Curran and Mark Stenhouse as Class I directors for three-year terms ending at the 2023 Annual Meeting or until successors are elected and qualified.
- Terrie Curran received 21,927,746 votes for, 3,038,844 against, 12,926 abstentions, and 298,049 broker non-votes.
- Mark Stenhouse received 24,928,297 votes for, 38,292 against, 12,927 abstentions, and 298,049 broker non-votes.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal 2020, with 25,264,636 votes for, no votes against, and 12,929 abstentions.
- The filing provides no financial guidance, operating outlook, material risk update, contingency, or unusual non-compensation item.
Key Facts to Verify
- Confirm the July 1, 2020 effective date and implementation of the revised executive salaries and target bonuses.
- Review the amended Bonus Plan when filed with the June 30, 2020 Form 10-Q.
- Verify the annualized compensation expense and any related disclosure in subsequent financial statements.
- Confirm the elected directors’ terms and Ernst & Young LLP’s appointment in subsequent proxy and periodic filings.